MedTrace Logo

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

NCT04764474 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

Conditions

  • Isocitrate Dehydrogenase Gene Mutation

Interventions

DRUG

HMPL-306

Administered orally QD in a 28-day continuous dosing treatment cycle

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Bo Zhang · Hutchison Medipharma Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2025-01-15
Completion
2025-01-15
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764474 on ClinicalTrials.gov